25 XP   0   0   10

Shanghai Kaibao Pharmaceutical
Buy, Hold or Sell?

Let's analyse Shanghai Kaibao Pharmaceutical together

PenkeI guess you are interested in Shanghai Kaibao Pharmaceutical. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Shanghai Kaibao Pharmaceutical. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Shanghai Kaibao Pharmaceutical

I send you an email if I find something interesting about Shanghai Kaibao Pharmaceutical.

Quick analysis of Shanghai Kaibao Pharmaceutical (30 sec.)










What can you expect buying and holding a share of Shanghai Kaibao Pharmaceutical? (30 sec.)

How much money do you get?

How much money do you get?
¥0.02
When do you have the money?
1 year
How often do you get paid?
82.5%

What is your share worth?

Current worth
¥3.65
Expected worth in 1 year
¥3.77
How sure are you?
92.5%

+ What do you gain per year?

Total Gains per Share
¥0.30
Return On Investment
4.9%

For what price can you sell your share?

Current Price per Share
¥6.16
Expected price per share
¥5.2892 - ¥6.18
How sure are you?
50%

1. Valuation of Shanghai Kaibao Pharmaceutical (5 min.)




Live pricePrice per Share (EOD)

¥6.16

Intrinsic Value Per Share

¥1.54 - ¥4.06

Total Value Per Share

¥5.19 - ¥7.72

2. Growth of Shanghai Kaibao Pharmaceutical (5 min.)




Is Shanghai Kaibao Pharmaceutical growing?

Current yearPrevious yearGrowGrow %
How rich?$527.8m$495.9m$42.2m7.9%

How much money is Shanghai Kaibao Pharmaceutical making?

Current yearPrevious yearGrowGrow %
Making money$9.2m$4.9m$4.3m46.6%
Net Profit Margin18.5%12.9%--

How much money comes from the company's main activities?

3. Financial Health of Shanghai Kaibao Pharmaceutical (5 min.)




What can you expect buying and holding a share of Shanghai Kaibao Pharmaceutical? (5 min.)

Welcome investor! Shanghai Kaibao Pharmaceutical's management wants to use your money to grow the business. In return you get a share of Shanghai Kaibao Pharmaceutical.

What can you expect buying and holding a share of Shanghai Kaibao Pharmaceutical?

First you should know what it really means to hold a share of Shanghai Kaibao Pharmaceutical. And how you can make/lose money.

Speculation

The Price per Share of Shanghai Kaibao Pharmaceutical is ¥6.16. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Shanghai Kaibao Pharmaceutical.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Shanghai Kaibao Pharmaceutical, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is ¥3.65. Based on the TTM, the Book Value Change Per Share is ¥0.03 per quarter. Based on the YOY, the Book Value Change Per Share is ¥0.16 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is ¥0.05 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Shanghai Kaibao Pharmaceutical.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 ¥% of Price per Share¥% of Price per Share¥% of Price per Share¥% of Price per Share¥% of Price per Share
Usd Eps0.010.1%0.010.1%0.000.1%0.010.1%0.010.1%
Usd Book Value Change Per Share-0.01-0.1%0.000.1%0.020.4%0.010.1%0.010.1%
Usd Dividend Per Share0.000.0%0.010.1%0.000.1%0.010.1%0.010.1%
Usd Total Gains Per Share-0.01-0.1%0.010.2%0.030.4%0.020.3%0.020.3%
Usd Price Per Share0.95-1.01-0.91-0.79-1.14-
Price to Earnings Ratio29.53-28.25-52.30-193.14-122.94-
Price-to-Total Gains Ratio-104.06--16.02-179.33-89.64-96.79-
Price to Book Ratio1.88-1.97-1.99-1.96-3.84-
Price-to-Total Gains Ratio-104.06--16.02-179.33-89.64-96.79-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.850696
Number of shares1175
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.010.01
Usd Book Value Change Per Share0.000.01
Usd Total Gains Per Share0.010.02
Gains per Quarter (1175 shares)12.1818.61
Gains per Year (1175 shares)48.7474.45
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
1292039314364
25839886386138
3885913794129212
411778186126172286
514698235157215360
6175117284189258434
7204137333220301508
8234156382252344582
9263176431283387656
10292195480315430730

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share4.00.00.0100.0%12.00.00.0100.0%19.01.00.095.0%39.01.00.097.5%56.01.00.098.2%
Book Value Change Per Share2.02.00.050.0%8.04.00.066.7%13.07.00.065.0%28.012.00.070.0%42.015.00.073.7%
Dividend per Share3.00.01.075.0%10.00.02.083.3%17.00.03.085.0%33.00.07.082.5%44.00.013.077.2%
Total Gains per Share2.02.00.050.0%9.03.00.075.0%17.03.00.085.0%37.03.00.092.5%54.03.00.094.7%

Fundamentals of Shanghai Kaibao Pharmaceutical

About Shanghai Kaibao Pharmaceutical

Shanghai Kaibao Pharmaceutical CO.,Ltd engages in the research, development, production, and sale of modern Chinese medicines primarily in China. Its primary products include Tanreqing injection for the treatment of pneumonia, acute and chronic bronchitis, and upper respiratory tract infection; Tanreqing capsules that clears heat and detoxifies and removes phlegm; tiopronin for injection, which improves liver function of various acute and chronic hepatitis; Tiopronin enteric-coated tablets for adjuvant treatment of chronic hepatitis; and Xiongdan dropping pills that clears heat, calms liver, and improves eyesight. The company was founded in 2000 and is based in Shanghai, China.

Fundamental data was last updated by Penke on 2024-04-16 11:37:04.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is less efficient in making profit.
Using its investors money, the company is inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating less efficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is overpriced.
Based on how much money comes from the company's main activities, the company is underpriced.

1.1. Profitability of Shanghai Kaibao Pharmaceutical.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Shanghai Kaibao Pharmaceutical earns for each ¥1 of revenue.

  • Above 10% is considered healthy but always compare Shanghai Kaibao Pharmaceutical to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Net Profit Margin of 19.8% means that ¥0.20 for each ¥1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Shanghai Kaibao Pharmaceutical:

  • The MRQ is 19.8%. The company is making a huge profit. +2
  • The TTM is 18.5%. The company is making a huge profit. +2
Trends
Current periodCompared to+/- 
MRQ19.8%TTM18.5%+1.2%
TTM18.5%YOY12.9%+5.7%
TTM18.5%5Y14.2%+4.3%
5Y14.2%10Y17.1%-2.9%
1.1.2. Return on Assets

Shows how efficient Shanghai Kaibao Pharmaceutical is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Shanghai Kaibao Pharmaceutical to the Drug Manufacturers - Specialty & Generic industry mean.
  • 1.4% Return on Assets means that Shanghai Kaibao Pharmaceutical generated ¥0.01 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Shanghai Kaibao Pharmaceutical:

  • The MRQ is 1.4%. Using its assets, the company is less efficient in making profit.
  • The TTM is 1.5%. Using its assets, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ1.4%TTM1.5%-0.1%
TTM1.5%YOY0.9%+0.6%
TTM1.5%5Y1.3%+0.2%
5Y1.3%10Y2.2%-0.9%
1.1.3. Return on Equity

Shows how efficient Shanghai Kaibao Pharmaceutical is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Shanghai Kaibao Pharmaceutical to the Drug Manufacturers - Specialty & Generic industry mean.
  • 1.6% Return on Equity means Shanghai Kaibao Pharmaceutical generated ¥0.02 for each ¥1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Shanghai Kaibao Pharmaceutical:

  • The MRQ is 1.6%. Using its investors money, the company is inefficient in making profit. -1
  • The TTM is 1.7%. Using its investors money, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ1.6%TTM1.7%-0.1%
TTM1.7%YOY1.0%+0.7%
TTM1.7%5Y1.4%+0.3%
5Y1.4%10Y2.6%-1.1%

1.2. Operating Efficiency of Shanghai Kaibao Pharmaceutical.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Shanghai Kaibao Pharmaceutical is operating .

  • Measures how much profit Shanghai Kaibao Pharmaceutical makes for each ¥1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Shanghai Kaibao Pharmaceutical to the Drug Manufacturers - Specialty & Generic industry mean.
  • An Operating Margin of 20.4% means the company generated ¥0.20  for each ¥1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Shanghai Kaibao Pharmaceutical:

  • The MRQ is 20.4%. The company is operating efficient. +1
  • The TTM is 13.3%. The company is operating less efficient.
Trends
Current periodCompared to+/- 
MRQ20.4%TTM13.3%+7.2%
TTM13.3%YOY12.1%+1.2%
TTM13.3%5Y14.1%-0.8%
5Y14.1%10Y8.2%+5.9%
1.2.2. Operating Ratio

Measures how efficient Shanghai Kaibao Pharmaceutical is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • An Operation Ratio of 1.00 means that the operating costs are ¥1.00 for each ¥1 in net sales.

Let's take a look of the Operating Ratio trends of Shanghai Kaibao Pharmaceutical:

  • The MRQ is 1.001. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.017. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.001TTM1.017-0.016
TTM1.017YOY1.109-0.092
TTM1.0175Y1.055-0.038
5Y1.05510Y0.640+0.415

1.3. Liquidity of Shanghai Kaibao Pharmaceutical.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Shanghai Kaibao Pharmaceutical is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A Current Ratio of 3.90 means the company has ¥3.90 in assets for each ¥1 in short-term debts.

Let's take a look of the Current Ratio trends of Shanghai Kaibao Pharmaceutical:

  • The MRQ is 3.904. The company is very able to pay all its short-term debts. +2
  • The TTM is 4.217. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ3.904TTM4.217-0.313
TTM4.217YOY10.568-6.351
TTM4.2175Y8.558-4.341
5Y8.55810Y4.679+3.879
1.3.2. Quick Ratio

Measures if Shanghai Kaibao Pharmaceutical is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Shanghai Kaibao Pharmaceutical to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Quick Ratio of 1.89 means the company can pay off ¥1.89 for each ¥1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Shanghai Kaibao Pharmaceutical:

  • The MRQ is 1.885. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 1.794. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ1.885TTM1.794+0.091
TTM1.794YOY3.280-1.485
TTM1.7945Y3.077-1.282
5Y3.07710Y2.801+0.276

1.4. Solvency of Shanghai Kaibao Pharmaceutical.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Shanghai Kaibao Pharmaceutical assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Shanghai Kaibao Pharmaceutical to Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Asset Ratio of 0.13 means that Shanghai Kaibao Pharmaceutical assets are financed with 13.2% credit (debt) and the remaining percentage (100% - 13.2%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Shanghai Kaibao Pharmaceutical:

  • The MRQ is 0.132. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.131. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.132TTM0.131+0.001
TTM0.131YOY0.107+0.024
TTM0.1315Y0.107+0.024
5Y0.10710Y0.122-0.014
1.4.2. Debt to Equity Ratio

Measures if Shanghai Kaibao Pharmaceutical is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Shanghai Kaibao Pharmaceutical to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Equity ratio of 15.2% means that company has ¥0.15 debt for each ¥1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Shanghai Kaibao Pharmaceutical:

  • The MRQ is 0.152. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.151. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.152TTM0.151+0.001
TTM0.151YOY0.120+0.032
TTM0.1515Y0.121+0.030
5Y0.12110Y0.140-0.019

2. Market Valuation of Shanghai Kaibao Pharmaceutical

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every ¥1 in earnings Shanghai Kaibao Pharmaceutical generates.

  • Above 15 is considered overpriced but always compare Shanghai Kaibao Pharmaceutical to the Drug Manufacturers - Specialty & Generic industry mean.
  • A PE ratio of 29.53 means the investor is paying ¥29.53 for every ¥1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Shanghai Kaibao Pharmaceutical:

  • The EOD is 26.478. Based on the earnings, the company is overpriced. -1
  • The MRQ is 29.530. Based on the earnings, the company is overpriced. -1
  • The TTM is 28.247. Based on the earnings, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD26.478MRQ29.530-3.052
MRQ29.530TTM28.247+1.283
TTM28.247YOY52.299-24.052
TTM28.2475Y193.136-164.889
5Y193.13610Y122.937+70.199
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Shanghai Kaibao Pharmaceutical:

  • The EOD is 14.760. Based on how much money comes from the company's main activities, the company is cheap. +2
  • The MRQ is 16.462. Based on how much money comes from the company's main activities, the company is underpriced. +1
  • The TTM is 20.465. Based on how much money comes from the company's main activities, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD14.760MRQ16.462-1.701
MRQ16.462TTM20.465-4.003
TTM20.465YOY-132.028+152.492
TTM20.4655Y-5.338+25.803
5Y-5.33810Y125.692-131.030
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Shanghai Kaibao Pharmaceutical is to cheap or to expensive compared to its book value.

Let's take a look of the Price to Book Ratio trends of Shanghai Kaibao Pharmaceutical:

  • The EOD is 1.686. Based on the equity, the company is underpriced. +1
  • The MRQ is 1.880. Based on the equity, the company is underpriced. +1
  • The TTM is 1.970. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD1.686MRQ1.880-0.194
MRQ1.880TTM1.970-0.090
TTM1.970YOY1.988-0.017
TTM1.9705Y1.965+0.005
5Y1.96510Y3.843-1.878
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Shanghai Kaibao Pharmaceutical compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.0660.030-319%0.158-142%0.066-200%0.055-221%
Book Value Per Share--3.6543.726-2%3.433+6%2.916+25%2.458+49%
Current Ratio--3.9044.217-7%10.568-63%8.558-54%4.679-17%
Debt To Asset Ratio--0.1320.131+0%0.107+23%0.107+23%0.122+8%
Debt To Equity Ratio--0.1520.151+0%0.120+27%0.121+26%0.140+9%
Dividend Per Share---0.045-100%0.025-100%0.048-100%0.064-100%
Eps--0.0580.066-12%0.034+70%0.042+39%0.057+3%
Free Cash Flow Per Share--0.1040.092+13%0.055+89%0.064+64%0.094+11%
Free Cash Flow To Equity Per Share--0.1040.047+122%0.042+148%0.034+207%0.078+35%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--4.063--------
Intrinsic Value_10Y_min--1.540--------
Intrinsic Value_1Y_max--0.381--------
Intrinsic Value_1Y_min--0.222--------
Intrinsic Value_3Y_max--1.164--------
Intrinsic Value_3Y_min--0.611--------
Intrinsic Value_5Y_max--1.971--------
Intrinsic Value_5Y_min--0.939--------
Market Cap6443360000.000-12%7186020000.0007667180000.000-6%6924520000.000+4%5965098316.850+20%8657996779.525-17%
Net Profit Margin--0.1980.185+7%0.129+54%0.142+39%0.171+16%
Operating Margin--0.2040.133+54%0.121+69%0.141+45%0.082+148%
Operating Ratio--1.0011.017-2%1.109-10%1.055-5%0.640+56%
Pb Ratio1.686-12%1.8801.970-5%1.988-5%1.965-4%3.843-51%
Pe Ratio26.478-12%29.53028.247+5%52.299-44%193.136-85%122.937-76%
Price Per Share6.160-12%6.8707.330-6%6.620+4%5.686+21%8.262-17%
Price To Free Cash Flow Ratio14.760-12%16.46220.465-20%-132.028+902%-5.338+132%125.692-87%
Price To Total Gains Ratio-93.310+10%-104.065-16.021-85%179.327-158%89.643-216%96.787-208%
Quick Ratio--1.8851.794+5%3.280-43%3.077-39%2.801-33%
Return On Assets--0.0140.015-8%0.009+50%0.013+8%0.022-38%
Return On Equity--0.0160.017-7%0.010+54%0.014+11%0.026-38%
Total Gains Per Share---0.0660.075-188%0.183-136%0.115-158%0.119-156%
Usd Book Value--527800036.853538199117.832-2%495938249.649+6%422526880.284+25%356059094.207+48%
Usd Book Value Change Per Share---0.0090.004-319%0.022-142%0.009-200%0.008-221%
Usd Book Value Per Share--0.5050.515-2%0.474+6%0.403+25%0.339+49%
Usd Dividend Per Share---0.006-100%0.003-100%0.007-100%0.009-100%
Usd Eps--0.0080.009-12%0.005+70%0.006+39%0.008+3%
Usd Free Cash Flow--15071230.04913282249.861+13%7965842.751+89%9218501.016+63%13586083.726+11%
Usd Free Cash Flow Per Share--0.0140.013+13%0.008+89%0.009+64%0.013+11%
Usd Free Cash Flow To Equity Per Share--0.0140.006+122%0.006+148%0.005+207%0.011+35%
Usd Market Cap889828016.000-12%992389362.0001058837558.000-6%956276212.000+4%823780077.557+20%1195669355.252-17%
Usd Price Per Share0.851-12%0.9491.012-6%0.914+4%0.785+21%1.141-17%
Usd Profit--8401563.2039263595.187-9%4944922.441+70%6024693.949+39%8170362.368+3%
Usd Revenue--42532117.60450861054.839-16%38172290.458+11%41785876.671+2%46365137.126-8%
Usd Total Gains Per Share---0.0090.010-188%0.025-136%0.016-158%0.016-156%
 EOD+5 -3MRQTTM+12 -23YOY+22 -135Y+22 -1310Y+17 -18

3.2. Fundamental Score

Let's check the fundamental score of Shanghai Kaibao Pharmaceutical based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1526.478
Price to Book Ratio (EOD)Between0-11.686
Net Profit Margin (MRQ)Greater than00.198
Operating Margin (MRQ)Greater than00.204
Quick Ratio (MRQ)Greater than11.885
Current Ratio (MRQ)Greater than13.904
Debt to Asset Ratio (MRQ)Less than10.132
Debt to Equity Ratio (MRQ)Less than10.152
Return on Equity (MRQ)Greater than0.150.016
Return on Assets (MRQ)Greater than0.050.014
Total6/10 (60.0%)

3.3. Technical Score

Let's check the technical score of Shanghai Kaibao Pharmaceutical based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5055.861
Ma 20Greater thanMa 505.964
Ma 50Greater thanMa 1006.181
Ma 100Greater thanMa 2006.326
OpenGreater thanClose6.100
Total1/5 (20.0%)



Latest Balance Sheet

Balance Sheet of 2023-09-30. Currency in CNY. All numbers in thousands.

Summary
Total Assets4,402,537
Total Liabilities580,669
Total Stockholder Equity3,821,550
 As reported
Total Liabilities 580,669
Total Stockholder Equity+ 3,821,550
Total Assets = 4,402,537

Assets

Total Assets4,402,537
Total Current Assets1,505,593
Long-term Assets2,896,944
Total Current Assets
Cash And Cash Equivalents 571,456
Short-term Investments 160,525
Net Receivables 566,498
Inventory 165,978
Other Current Assets 41,135
Total Current Assets  (as reported)1,505,593
Total Current Assets  (calculated)1,505,593
+/- 0
Long-term Assets
Property Plant Equipment 294,751
Goodwill 9,040
Intangible Assets 44,097
Other Assets 1,324,939
Long-term Assets  (as reported)2,896,944
Long-term Assets  (calculated)1,672,827
+/- 1,224,117

Liabilities & Shareholders' Equity

Total Current Liabilities385,663
Long-term Liabilities195,006
Total Stockholder Equity3,821,550
Total Current Liabilities
Accounts payable 114,376
Other Current Liabilities 267,163
Total Current Liabilities  (as reported)385,663
Total Current Liabilities  (calculated)381,538
+/- 4,125
Long-term Liabilities
Other Liabilities 195,006
Long-term Liabilities  (as reported)195,006
Long-term Liabilities  (calculated)195,006
+/- 0
Total Stockholder Equity
Common Stock1,046,000
Retained Earnings 1,918,513
Other Stockholders Equity 848,412
Total Stockholder Equity (as reported)3,821,550
Total Stockholder Equity (calculated)3,812,925
+/- 8,625
Other
Capital Stock1,046,000
Common Stock Shares Outstanding 1,046,000
Net Invested Capital 3,821,550
Net Tangible Assets 3,768,413
Net Working Capital 1,119,930
Property Plant and Equipment Gross 294,751



Balance Sheet

Currency in CNY. All numbers in thousands.

 Trend2023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-312009-09-302009-06-302008-12-312007-12-312006-12-31
> Total Assets 
109,035
161,606
229,875
270,041
349,424
1,345,390
1,226,773
1,240,047
1,333,686
1,370,399
1,397,902
1,375,750
1,422,059
1,452,404
1,556,339
1,434,122
1,549,608
1,561,085
1,691,039
1,665,171
1,754,547
1,770,810
1,879,796
1,860,352
1,977,990
2,117,367
2,303,840
2,484,353
2,465,763
2,426,669
2,535,454
2,517,220
2,563,321
2,527,916
2,654,752
2,736,616
2,694,183
2,679,724
2,850,559
2,769,653
2,787,662
2,747,389
2,889,018
2,808,911
2,773,254
2,842,499
2,943,004
2,820,944
2,865,227
2,877,284
2,928,301
2,907,685
3,285,095
3,355,817
3,622,340
4,958,543
4,156,932
4,259,271
4,757,637
4,529,990
4,402,537
4,402,5374,529,9904,757,6374,259,2714,156,9324,958,5433,622,3403,355,8173,285,0952,907,6852,928,3012,877,2842,865,2272,820,9442,943,0042,842,4992,773,2542,808,9112,889,0182,747,3892,787,6622,769,6532,850,5592,679,7242,694,1832,736,6162,654,7522,527,9162,563,3212,517,2202,535,4542,426,6692,465,7632,484,3532,303,8402,117,3671,977,9901,860,3521,879,7961,770,8101,754,5471,665,1711,691,0391,561,0851,549,6081,434,1221,556,3391,452,4041,422,0591,375,7501,397,9021,370,3991,333,6861,240,0471,226,7731,345,390349,424270,041229,875161,606109,035
   > Total Current Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,198,995
2,225,388
2,159,600
2,307,956
2,238,272
2,210,467
2,263,680
2,374,810
2,263,277
2,201,860
2,219,863
2,270,186
2,235,364
2,208,021
2,254,418
2,387,073
2,280,857
2,357,413
1,574,429
1,658,185
1,470,941
1,505,593
1,505,5931,470,9411,658,1851,574,4292,357,4132,280,8572,387,0732,254,4182,208,0212,235,3642,270,1862,219,8632,201,8602,263,2772,374,8102,263,6802,210,4672,238,2722,307,9562,159,6002,225,3882,198,995000000000000000000000000000000000000000
       Cash And Cash Equivalents 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
702,955
797,047
547,054
899,100
745,145
941,336
809,523
1,249,079
1,300,360
1,294,228
1,307,082
1,273,165
1,318,345
1,332,195
1,344,949
1,347,030
1,338,511
1,443,888
694,690
715,115
582,751
571,456
571,456582,751715,115694,6901,443,8881,338,5111,347,0301,344,9491,332,1951,318,3451,273,1651,307,0821,294,2281,300,3601,249,079809,523941,336745,145899,100547,054797,047702,955000000000000000000000000000000000000000
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
328,000
0
569,664
374,912
473,435
308,013
485,566
237,556
124,092
114,125
114,647
68,607
91,230
68,907
51,262
115,959
108,569
158,651
136,075
93,394
32,885
160,525
160,52532,88593,394136,075158,651108,569115,95951,26268,90791,23068,607114,647114,125124,092237,556485,566308,013473,435374,912569,6640328,000000000000000000000000000000000000000000
       Net Receivables 
61,863
89,873
111,271
122,810
128,367
121,653
138,682
145,185
168,296
205,777
245,979
264,396
281,232
322,262
352,219
326,853
368,124
346,416
378,906
413,502
461,143
427,316
497,065
565,639
578,935
540,196
717,015
902,443
813,629
685,442
769,522
808,869
769,346
639,440
725,683
827,538
739,036
745,600
895,761
860,306
722,417
767,337
499,124
454,671
407,786
721,066
689,438
574,448
505,884
562,386
692,710
566,318
557,053
614,760
684,761
580,779
585,913
374,675
671,133
662,941
566,498
566,498662,941671,133374,675585,913580,779684,761614,760557,053566,318692,710562,386505,884574,448689,438721,066407,786454,671499,124767,337722,417860,306895,761745,600739,036827,538725,683639,440769,346808,869769,522685,442813,629902,443717,015540,196578,935565,639497,065427,316461,143413,502378,906346,416368,124326,853352,219322,262281,232264,396245,979205,777168,296145,185138,682121,653128,367122,810111,27189,87361,863
       Other Current Assets 
802
2,915
16,102
18,487
79,663
26,741
28,582
5,576
30,566
55,019
66,773
61,607
68,653
38,673
48,547
46,192
51,157
70,803
113,760
81,391
91,231
70,442
78,935
10,986
9,395
64,325
75,041
75,038
80,431
27,364
35,151
46,834
66,905
15,010
418,365
49,080
524,916
28,787
404,732
36,623
426,144
17,913
39,098
548
7
3,818
21,646
66,561
90,530
8,081
33,739
42,199
57,334
19,990
74,681
95,608
7,703
3,841
21,902
39,993
41,135
41,13539,99321,9023,8417,70395,60874,68119,99057,33442,19933,7398,08190,53066,56121,6463,818754839,09817,913426,14436,623404,73228,787524,91649,080418,36515,01066,90546,83435,15127,36480,43175,03875,04164,3259,39510,98678,93570,44291,23181,391113,76070,80351,15746,19248,54738,67368,65361,60766,77355,01930,5665,57628,58226,74179,66318,48716,1022,915802
   > Long-term Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
581,061
570,639
562,787
578,819
568,194
557,666
663,367
657,422
658,115
672,321
1,077,074
1,101,399
1,235,267
2,677,686
1,799,519
2,684,842
3,099,452
3,059,048
2,896,944
2,896,9443,059,0483,099,4522,684,8421,799,5192,677,6861,235,2671,101,3991,077,074672,321658,115657,422663,367557,666568,194578,819562,787570,639581,061000000000000000000000000000000000000000000
       Property Plant Equipment 
30,545
31,325
34,446
89,422
52,513
148,437
126,335
196,262
194,632
214,895
185,538
239,951
211,734
251,223
233,422
255,721
227,258
252,519
238,969
286,224
274,700
355,656
309,875
310,404
308,362
347,188
337,832
414,770
405,769
401,089
395,916
384,141
373,912
372,849
362,865
361,240
374,533
374,385
367,970
369,438
362,008
353,288
343,948
333,717
325,939
326,810
316,441
306,976
307,190
295,866
290,851
285,452
288,330
307,782
299,322
303,615
310,698
304,663
301,472
301,588
294,751
294,751301,588301,472304,663310,698303,615299,322307,782288,330285,452290,851295,866307,190306,976316,441326,810325,939333,717343,948353,288362,008369,438367,970374,385374,533361,240362,865372,849373,912384,141395,916401,089405,769414,770337,832347,188308,362310,404309,875355,656274,700286,224238,969252,519227,258255,721233,422251,223211,734239,951185,538214,895194,632196,262126,335148,43752,51389,42234,44631,32530,545
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
18,500
18,500
18,500
18,500
13,794
13,794
13,794
13,794
9,040
9,040
9,040
9,040
9,0409,0409,0409,04013,79413,79413,79413,79418,50018,50018,50018,5000000000000000000000000000000000000000000000000000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
152,045
152,045
182,436
185,170
185,825
186,487
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000186,487185,825185,170182,436152,045152,045000000000000000000000000000000000000000
       Intangible Assets 
1,323
966
3,322
100
27,309
25
27,599
0
27,279
25
26,959
26,799
26,639
0
26,320
26,160
26,000
0
43,067
0
42,526
0
48,983
48,756
48,529
47,123
46,896
51,633
51,406
46,793
46,409
46,024
45,639
45,379
44,994
44,609
44,224
43,749
43,351
42,952
42,554
42,120
41,721
2,930
40,924
41,333
40,948
40,461
40,076
45,263
44,681
44,239
43,779
42,903
42,320
41,738
41,155
44,228
43,457
44,932
44,097
44,09744,93243,45744,22841,15541,73842,32042,90343,77944,23944,68145,26340,07640,46140,94841,33340,9242,93041,72142,12042,55442,95243,35143,74944,22444,60944,99445,37945,63946,02446,40946,79351,40651,63346,89647,12348,52948,75648,983042,526043,067026,00026,16026,320026,63926,79926,9592527,279027,5992527,3091003,3229661,323
       Long-term Assets Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
185,170
185,825
53,100
10,553
10,553
10,553
362,200
20,446
20,446
36,000
56,446
10,755
8,453
0
0
996,495
1,092,967
1,308,233
1,308,587
1,308,5871,308,2331,092,967996,495008,45310,75556,44636,00020,44620,446362,20010,55310,55310,55353,100185,825185,170000000000000000000000000000000000000000000
> Total Liabilities 
71,799
84,644
102,951
138,063
197,183
199,200
64,470
73,748
121,736
133,388
124,781
124,087
124,022
117,974
171,105
135,338
186,686
142,287
203,887
212,103
218,084
164,717
193,737
207,569
234,201
232,722
326,158
524,365
440,692
421,159
446,831
402,664
381,313
327,605
363,746
341,792
336,499
314,258
385,512
328,200
290,894
262,260
346,857
312,736
240,928
273,008
320,804
279,111
294,598
298,960
292,739
278,949
249,514
310,905
411,943
545,206
460,966
498,241
642,780
639,068
580,669
580,669639,068642,780498,241460,966545,206411,943310,905249,514278,949292,739298,960294,598279,111320,804273,008240,928312,736346,857262,260290,894328,200385,512314,258336,499341,792363,746327,605381,313402,664446,831421,159440,692524,365326,158232,722234,201207,569193,737164,717218,084212,103203,887142,287186,686135,338171,105117,974124,022124,087124,781133,388121,73673,74864,470199,200197,183138,063102,95184,64471,799
   > Total Current Liabilities 
71,799
84,644
102,951
138,063
197,183
186,200
51,470
60,748
109,061
118,568
110,351
110,047
110,372
103,364
156,897
114,826
164,771
118,750
181,057
189,708
196,439
142,202
171,953
186,515
213,878
211,018
296,385
474,306
392,817
375,759
402,953
360,306
339,146
286,567
324,229
303,795
300,022
279,469
352,243
295,491
259,706
235,154
320,395
286,435
216,824
240,024
289,412
232,121
233,792
237,547
231,824
220,136
191,523
190,680
274,082
190,791
240,908
295,959
393,630
428,702
385,663
385,663428,702393,630295,959240,908190,791274,082190,680191,523220,136231,824237,547233,792232,121289,412240,024216,824286,435320,395235,154259,706295,491352,243279,469300,022303,795324,229286,567339,146360,306402,953375,759392,817474,306296,385211,018213,878186,515171,953142,202196,439189,708181,057118,750164,771114,826156,897103,364110,372110,047110,351118,568109,06160,74851,470186,200197,183138,063102,95184,64471,799
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
35,723
35,723
35,723
35,723
0
0
0
0
0
0
0
0
0
0
0
0000000000035,72335,72335,72335,7230000000000000000000000000000000000000000000000
       Accounts payable 
17,251
2,886
6,764
8,163
4,065
8,230
2,494
6,070
38,158
32,182
22,068
27,559
25,404
14,996
49,654
15,356
67,403
18,523
60,401
59,229
60,679
18,670
18,453
32,601
57,369
38,630
79,532
180,240
154,274
87,259
100,562
97,409
85,370
60,741
81,543
77,220
86,974
60,874
123,554
78,254
41,800
64,250
123,395
121,119
54,984
77,926
104,726
58,821
43,005
62,229
57,134
78,960
72,468
75,016
118,970
61,049
81,910
91,011
159,766
182,000
114,376
114,376182,000159,76691,01181,91061,049118,97075,01672,46878,96057,13462,22943,00558,821104,72677,92654,984121,119123,39564,25041,80078,254123,55460,87486,97477,22081,54360,74185,37097,409100,56287,259154,274180,24079,53238,63057,36932,60118,45318,67060,67959,22960,40118,52367,40315,35649,65414,99625,40427,55922,06832,18238,1586,0702,4948,2304,0658,1636,7642,88617,251
       Other Current Liabilities 
48,048
81,758
76,887
60,900
63,918
59,470
48,976
54,678
70,903
86,386
88,283
82,488
84,968
88,368
107,243
99,470
97,368
100,227
120,656
130,479
135,760
123,532
153,500
153,914
156,508
172,389
216,853
264,067
238,543
288,500
302,390
262,897
253,775
225,826
242,686
226,575
213,048
202,595
228,689
179,093
216,189
143,881
195,971
143,247
160,787
140,948
148,065
122,700
154,122
126,126
173,736
105,747
114,381
99,744
153,869
127,782
156,601
12,236
232,903
156,708
267,163
267,163156,708232,90312,236156,601127,782153,86999,744114,381105,747173,736126,126154,122122,700148,065140,948160,787143,247195,971143,881216,189179,093228,689202,595213,048226,575242,686225,826253,775262,897302,390288,500238,543264,067216,853172,389156,508153,914153,500123,532135,760130,479120,656100,22797,36899,470107,24388,36884,96882,48888,28386,38670,90354,67848,97659,47063,91860,90076,88781,75848,048
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
26,462
26,302
24,103
32,984
31,392
46,990
60,805
61,413
60,915
58,814
57,991
120,225
137,861
354,415
220,058
202,282
249,150
210,366
195,006
195,006210,366249,150202,282220,058354,415137,861120,22557,99158,81460,91561,41360,80546,99031,39232,98424,10326,30226,462000000000000000000000000000000000000000000
       Other Liabilities 
0
0
0
0
0
13,000
13,000
13,000
12,675
14,820
14,430
14,040
13,650
14,610
14,208
20,512
21,915
23,537
22,830
22,395
21,645
22,515
21,784
21,054
20,323
21,703
29,773
50,059
47,876
45,400
43,878
42,358
42,167
41,038
39,518
37,997
36,477
34,471
32,951
32,709
31,189
27,105
26,462
26,302
24,103
32,984
31,392
46,990
60,805
61,413
60,915
58,814
57,991
120,225
137,861
354,415
220,058
0
249,150
210,366
195,006
195,006210,366249,1500220,058354,415137,861120,22557,99158,81460,91561,41360,80546,99031,39232,98424,10326,30226,46227,10531,18932,70932,95134,47136,47737,99739,51841,03842,16742,35843,87845,40047,87650,05929,77321,70320,32321,05421,78422,51521,64522,39522,83023,53721,91520,51214,20814,61013,65014,04014,43014,82012,67513,00013,00013,00000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
597
533
469
405
341
277
213
149
85
21
0
0
0
0
0
0
0
0
0
295
322
377
3773222950000000002185149213277341405469533597000000000000000000000000000000000000000
> Total Stockholder Equity
37,236
75,082
126,924
131,978
152,240
1,146,191
1,162,303
1,166,299
1,211,949
1,237,011
1,273,122
1,251,663
1,298,037
1,334,430
1,385,234
1,298,784
1,362,922
1,418,798
1,487,152
1,453,068
1,536,463
1,606,093
1,686,059
1,652,783
1,743,789
1,884,645
1,977,683
1,959,988
2,025,070
2,005,509
2,088,623
2,114,556
2,182,008
2,200,311
2,291,006
2,394,824
2,357,684
2,365,466
2,465,047
2,441,453
2,496,768
2,485,129
2,542,161
2,496,175
2,532,327
2,569,492
2,622,200
2,541,833
2,570,629
2,578,324
2,635,562
2,628,735
3,035,581
3,044,914
3,210,894
4,413,844
3,696,537
3,761,753
4,115,640
3,890,519
3,821,550
3,821,5503,890,5194,115,6403,761,7533,696,5374,413,8443,210,8943,044,9143,035,5812,628,7352,635,5622,578,3242,570,6292,541,8332,622,2002,569,4922,532,3272,496,1752,542,1612,485,1292,496,7682,441,4532,465,0472,365,4662,357,6842,394,8242,291,0062,200,3112,182,0082,114,5562,088,6232,005,5092,025,0701,959,9881,977,6831,884,6451,743,7891,652,7831,686,0591,606,0931,536,4631,453,0681,487,1521,418,7981,362,9221,298,7841,385,2341,334,4301,298,0371,251,6631,273,1221,237,0111,211,9491,166,2991,162,3031,146,191152,240131,978126,92475,08237,236
   Common Stock
12,000
12,000
82,200
82,200
82,200
109,600
109,600
175,360
175,360
175,360
175,360
263,040
263,040
263,040
263,040
263,040
263,040
263,040
263,040
526,080
526,080
526,080
526,080
631,296
631,296
640,376
640,376
833,685
833,685
833,685
833,685
829,546
829,432
829,432
824,226
1,071,494
1,071,494
1,071,494
1,071,494
1,071,494
1,071,494
1,071,494
1,071,494
1,071,494
1,071,494
1,046,000
1,046,000
1,046,000
1,046,000
1,046,000
1,046,000
1,046,000
1,046,000
1,046,000
1,046,000
1,046,000
1,046,000
0
1,046,000
1,046,000
1,046,000
1,046,0001,046,0001,046,00001,046,0001,046,0001,046,0001,046,0001,046,0001,046,0001,046,0001,046,0001,046,0001,046,0001,046,0001,046,0001,071,4941,071,4941,071,4941,071,4941,071,4941,071,4941,071,4941,071,4941,071,4941,071,494824,226829,432829,432829,546833,685833,685833,685833,685640,376640,376631,296631,296526,080526,080526,080526,080263,040263,040263,040263,040263,040263,040263,040263,040175,360175,360175,360175,360109,600109,60082,20082,20082,20012,00012,000
   Retained Earnings 
21,704
55,099
27,946
30,001
48,212
65,016
81,128
85,124
130,774
143,390
179,501
158,042
204,416
224,320
275,123
188,674
252,812
284,468
352,823
318,738
402,133
439,882
618,174
584,898
675,904
750,779
839,924
857,315
922,397
950,811
1,033,925
1,059,318
1,127,801
1,150,984
1,241,679
1,345,497
1,308,357
1,285,348
1,384,928
1,361,335
1,416,650
1,405,011
1,247,676
1,222,625
1,277,925
1,466,502
1,519,211
1,438,844
1,467,640
1,468,025
1,525,262
1,518,436
1,552,144
1,576,759
1,634,395
1,607,236
1,643,071
1,567,755
1,865,329
1,857,677
1,918,513
1,918,5131,857,6771,865,3291,567,7551,643,0711,607,2361,634,3951,576,7591,552,1441,518,4361,525,2621,468,0251,467,6401,438,8441,519,2111,466,5021,277,9251,222,6251,247,6761,405,0111,416,6501,361,3351,384,9281,285,3481,308,3571,345,4971,241,6791,150,9841,127,8011,059,3181,033,925950,811922,397857,315839,924750,779675,904584,898618,174439,882402,133318,738352,823284,468252,812188,674275,123224,320204,416158,042179,501143,390130,77485,12481,12865,01648,21230,00127,94655,09921,704
   Capital Surplus 0000000000000000000000000000000000000000000000000000000000000
   Treasury Stock000000000000000000000000000-29,830-30,866-30,866-55,367-55,36700000000000000000000000000000
   Other Stockholders Equity 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
48,365
48,365
48,365
48,365
55,675
55,675
55,675
428,813
413,531
521,874
1,751,984
998,841
0
1,195,687
978,218
848,412
848,412978,2181,195,6870998,8411,751,984521,874413,531428,81355,67555,67555,67548,36548,36548,36548,365000000000000000000000000000000000000000000000



Balance Sheet

Currency in CNY. All numbers in thousands.




Cash Flow

Currency in CNY. All numbers in thousands.




Income Statement

Currency in CNY. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue1,473,166
Cost of Revenue-316,166
Gross Profit1,157,0001,157,000
 
Operating Income (+$)
Gross Profit1,157,000
Operating Expense-1,185,524
Operating Income287,642-28,524
 
Operating Expense (+$)
Research Development93,603
Selling General Administrative726,505
Selling And Marketing Expenses-
Operating Expense1,185,524820,108
 
Net Interest Income (+$)
Interest Income41,929
Interest Expense--
Other Finance Cost-1,340
Net Interest Income43,269
 
Pretax Income (+$)
Operating Income287,642
Net Interest Income43,269
Other Non-Operating Income Expenses-
Income Before Tax (EBT)321,112287,642
EBIT - interestExpense = 0
268,316
268,316
Interest Expense-
Earnings Before Interest and Taxes (EBIT)-321,112
Earnings Before Interest and Taxes (EBITDA)-
 
After tax Income (+$)
Income Before Tax321,112
Tax Provision-53,240
Net Income From Continuing Ops267,872267,872
Net Income268,316
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net--43,269
 

Technical Analysis of Shanghai Kaibao Pharmaceutical
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Shanghai Kaibao Pharmaceutical. The general trend of Shanghai Kaibao Pharmaceutical is BEARISH with 71.4% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Shanghai Kaibao Pharmaceutical's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-71.4%) Bearish trend (71.4%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Shanghai Kaibao Pharmaceutical.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is -1/(-1 +1).

  • Around resistance: The price is trading arround resistance levels. This can be considered as a potential exit level. -1

The bullish price targets are: 6.18 < 6.18 < 6.18.

The bearish price targets are: 5.58 > 5.46 > 5.2892.

Tweet this
Shanghai Kaibao Pharmaceutical Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Shanghai Kaibao Pharmaceutical. The current mas is .

The long score for the Moving Averages is 2/14.
The longshort score for the Moving Averages is -10/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Shanghai Kaibao Pharmaceutical Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Shanghai Kaibao Pharmaceutical. The current macd is -0.03481129.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Shanghai Kaibao Pharmaceutical price going up in the near term. +2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Shanghai Kaibao Pharmaceutical. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Shanghai Kaibao Pharmaceutical price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Shanghai Kaibao Pharmaceutical Daily Moving Average Convergence/Divergence (MACD) ChartShanghai Kaibao Pharmaceutical Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Shanghai Kaibao Pharmaceutical. The current adx is 17.55.

The long score for the Directional Movement Index (DMI) is 1/7.
The longshort score for the Directional Movement Index (DMI) is 1/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Shanghai Kaibao Pharmaceutical shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Shanghai Kaibao Pharmaceutical Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Shanghai Kaibao Pharmaceutical. The current sar is 5.7212282.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Shanghai Kaibao Pharmaceutical Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Shanghai Kaibao Pharmaceutical. The current rsi is 55.86. The current phase is Correction in bear market.

The long score for the Relative Strength Index (RSI) is 4/13.
The longshort score for the Relative Strength Index (RSI) is 4/(-13 +13).

  • Correction in bear market: Extended price decline in a downtrend, significant pullback. Consider reducing exposure, wait for signs of trend reversal.
  • Trending up: The RSI is trending up. +1
Shanghai Kaibao Pharmaceutical Daily Relative Strength Index (RSI) ChartShanghai Kaibao Pharmaceutical Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Shanghai Kaibao Pharmaceutical. The current phase is Overbought in bear market.

The long score for the Stochastic Oscillator is 5/6.
The longshort score for the Stochastic Oscillator is 4/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH > 80: The STOCH %K is above 80 and overbought. +2
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Shanghai Kaibao Pharmaceutical price going up in the near term. +2
  • Trending down: The STOCH %K is trending down. -1
Shanghai Kaibao Pharmaceutical Daily Stochastic Oscillator ChartShanghai Kaibao Pharmaceutical Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Shanghai Kaibao Pharmaceutical. The current cci is 102.65.

The long score for the Commodity Channel Index (CCI) is 1/1.
The longshort score for the Commodity Channel Index (CCI) is 1/(-1 +1).

  • CCI > 100: The CCI is above 100, it indicates that the price is significantly above its average, suggesting a potential overbought condition. +1
Shanghai Kaibao Pharmaceutical Daily Commodity Channel Index (CCI) ChartShanghai Kaibao Pharmaceutical Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Shanghai Kaibao Pharmaceutical. The current cmo is 26.60.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Shanghai Kaibao Pharmaceutical Daily Chande Momentum Oscillator (CMO) ChartShanghai Kaibao Pharmaceutical Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Shanghai Kaibao Pharmaceutical. The current willr is -9.375.

The long score for the Williams %R is 1/1.
The longshort score for the Williams %R is 1/(-1 +1).

  • WILLR > -20: The Williams %R is above -20. This indicates that the price is in overbought territory, suggesting a potential price correction or trend reversal to the downside. +1
Shanghai Kaibao Pharmaceutical Daily Williams %R ChartShanghai Kaibao Pharmaceutical Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Shanghai Kaibao Pharmaceutical.

Shanghai Kaibao Pharmaceutical Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Shanghai Kaibao Pharmaceutical. The current atr is 0.15541665.

Shanghai Kaibao Pharmaceutical Daily Average True Range (ATR) ChartShanghai Kaibao Pharmaceutical Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Shanghai Kaibao Pharmaceutical. The current obv is 1,390,315,041.

Shanghai Kaibao Pharmaceutical Daily On-Balance Volume (OBV) ChartShanghai Kaibao Pharmaceutical Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Shanghai Kaibao Pharmaceutical. The current mfi is 68.87.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Shanghai Kaibao Pharmaceutical Daily Money Flow Index (MFI) ChartShanghai Kaibao Pharmaceutical Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Shanghai Kaibao Pharmaceutical.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-12-04STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-05MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-06CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-07WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-11STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-13SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-15STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-18SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-19DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2023-12-20DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-21DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2023-12-22STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2023-12-26BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2023-12-27STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-02DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-01-03SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-01-04STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-05DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-01-08SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-10STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-11RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-16STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-22STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-23STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-24RSI LONG ENTRY SHORT CLOSE30 crossover to upside
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-01-25MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-29STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-30DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-02SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-02-05STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-06STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-20DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-21STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-22STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-26STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-27STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-28STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-29CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-07CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-11CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-12CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-13STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-18CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-03-19STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-22MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-25SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-26DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-27DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-03-28DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-01DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-04-02STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-03DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-04-08CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-10STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-12CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-16STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-17RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-19STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-22SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-24MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-04-25CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-26WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-04-29DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-04-30CCI LONG ENTRY SHORT CLOSE100 crossover to upside

6.3. Candlestick Patterns

Shanghai Kaibao Pharmaceutical Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Shanghai Kaibao Pharmaceutical based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5055.861
Ma 20Greater thanMa 505.964
Ma 50Greater thanMa 1006.181
Ma 100Greater thanMa 2006.326
OpenGreater thanClose6.100
Total1/5 (20.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Shanghai Kaibao Pharmaceutical with someone you think should read this too:
  • Are you bullish or bearish on Shanghai Kaibao Pharmaceutical? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Shanghai Kaibao Pharmaceutical? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Shanghai Kaibao Pharmaceutical

I send you an email if I find something interesting about Shanghai Kaibao Pharmaceutical.


Comments

How you think about this?

Leave a comment

Stay informed about Shanghai Kaibao Pharmaceutical.

Receive notifications about Shanghai Kaibao Pharmaceutical in your mailbox!